id: NEW:statin_therapy_to_NEW:nonalcoholic_steatohepatitis_nash
name: Statin Therapy â†’ Nonalcoholic Steatohepatitis (NASH)
from_node:
  node_id: NEW:statin_therapy
  node_name: Statin Therapy
to_node:
  node_id: NEW:nonalcoholic_steatohepatitis_nash
  node_name: Nonalcoholic Steatohepatitis (NASH)
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Statins inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis
  and improving lipid metabolism in the liver'
- 'Step 2: Statins exert anti-inflammatory effects by reducing pro-inflammatory cytokines
  and systemic inflammation in NASH patients'
- 'Step 3: Statins demonstrate antifibrotic properties, reducing hepatic stellate
  cell activation and collagen deposition'
- 'Step 4: Statins modulate intestinal microbiota composition, reducing harmful inflammatory
  bacteria and gut-derived endotoxins'
- 'Step 5: The combined lipid-lowering, anti-inflammatory, antifibrotic, and microbiome-modulating
  effects reduce hepatic steatosis, inflammation, and fibrosis characteristic of NASH'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'Shiqin Zhang et al. 2024. A Systematic Review of Statins for
    the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism
    of Action. Molecules.'
  supporting_citations: []
description: Statins provide multifaceted therapeutic benefits in NASH through their
  primary lipid-modulating effects combined with anti-inflammatory and antifibrotic
  properties. Beyond cholesterol reduction, statins reduce hepatic inflammation, inhibit
  fibrosis progression, and modulate the gut microbiota to reduce systemic inflammation.
  This systematic review synthesizes evidence from human and animal studies demonstrating
  statin safety and efficacy in NAFLD/NASH populations.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
moderators:
- name: Cardiovascular disease comorbidity
  direction: strengthens
  strength: moderate
  description: NASH patients with CVD comorbidity may derive additional benefit from
    statins given shared risk factors and CVD being the leading cause of death in
    NASH patients
- name: Gut microbiota composition
  direction: strengthens
  strength: moderate
  description: Patients with dysbiotic gut microbiota may experience greater benefit
    through statin-mediated modulation of inflammatory microbiota
